These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8570541)

  • 1. Evidence for the lack of a human metabolic isotope effect of a deuterium analog of fluphenazine.
    Hadad S; Hubbard JW; McKay G; Hawes EM; Shrikhande S; Midha KK
    Pharm Res; 1995 Sep; 12(9):1388-90. PubMed ID: 8570541
    [No Abstract]   [Full Text] [Related]  

  • 2. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing from oral to depot fluphenazine.
    Yadalam KG; Simpson GM
    J Clin Psychiatry; 1988 Sep; 49(9):346-8. PubMed ID: 3417620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
    Viala A; Ba B; Durand A; Gouezo F; Hou N; Jørgensen A
    Psychopharmacology (Berl); 1988; 94(3):293-7. PubMed ID: 2895936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard v optimal dose.
    Ostow M
    Arch Gen Psychiatry; 1984 Jul; 41(7):726-7. PubMed ID: 6145401
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosage of oral and depot fluphenazine.
    Schiff AA
    Am J Psychiatry; 1989 Sep; 146(9):1233. PubMed ID: 2764188
    [No Abstract]   [Full Text] [Related]  

  • 11. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who receives long-acting antipsychotic medications?
    Glazer WM
    Psychiatr Serv; 2007 Apr; 58(4):437. PubMed ID: 17412839
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
    Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
    Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of fluphenazine, a highly lipophilic drug, estimated from a pulse dose of a stable isotopomer in dogs at steady state.
    Hubbard JW; Hadad S; Luo JP; McKay G; Midha KK
    J Pharm Sci; 1999 Sep; 88(9):918-21. PubMed ID: 10479354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of neuroleptic dosage.
    Teicher MH; Baldessarini RJ
    Arch Gen Psychiatry; 1985 Jun; 42(6):636-7. PubMed ID: 2860885
    [No Abstract]   [Full Text] [Related]  

  • 16. Risks versus benefits of different types of long-acting injectable antipsychotics.
    McEvoy JP
    J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
    Müller P
    Nervenarzt; 1983 Sep; 54(9):477-85. PubMed ID: 6138720
    [No Abstract]   [Full Text] [Related]  

  • 18. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY; Wu PC; Chen CY; Chen YC
    Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil.
    Luo JP; Hubbard JW; Midha KK
    Pharm Res; 1997 Aug; 14(8):1079-84. PubMed ID: 9279892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
    Johnson DA
    Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.